Combining radiotherapy with CAR-T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has achieved significant success in treating hematological malignancies. However, compared to its efficacy against hematologic cancers, the application of CAR-T cell therapy for solid tumors still faces several challenges. Radiotherapy, an important component in the treatment of solid tumors, has recently attracted widespread attention because of its immunomodulatory effects. Combined radiotherapy may overcome the limitations of CAR-T cell therapy for solid tumors. This review discusses the theoretical foundations of combined radiation therapy and CAR-T cell therapy, along with preclinical and clinical research progress. Additionally, this study provides an innovative exploration of key factors to be considered when combining these two therapies. These factors include radiation dose, mode, radiation type, and timing and scheduling of the combined treatment. This review offers new perspectives on future research directions and highlights critical issues that remain to be addressed.

Keywords

Chimeric antigen receptor -T cell therapy / Immunotherapy / Neoplasms / Radiotherapy / Tumor microenvironment

References

[1] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021; 21(3): 145-161.

[2] Zietman AL, Yom SS. Radiation Therapy and the Immune System: A Scientific Revolution in the Making. Int J Radiat Oncol Biol Phys. 2020; 108(1): 1-2.

[3] Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024; 23(6): 445-460.

[4] Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014; 3:e28518.

[5] Wang L, Lynch C, Pitroda SP, et al. Radiotherapy and immunology. J Exp Med. 2024; 221(7)

[6] Hovhannisyan L, Riether C, Aebersold DM, Medova M, Zimmer Y. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. Mol Cancer. 2023; 22(1): 82.

[7] Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Res. 2018; 78(4): 1031-1043.

[8] Murty S, Haile ST, Beinat C, et al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology. 2020; 9(1)e1757360.

[9] Ventin M, Cattaneo G, Maggs L, et al. B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers. Front Oncol. 2023; 13:1193963.

[10] DeSelm C, Palomba ML, Yahalom J, et al. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Mol Ther. 2018; 26(11): 2542-2552.

[11] Köseer AS, Loureiro LR, Jureczek J, et al. Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. Cancers. 2022; 14(7):1677.

[12] Arndt C, Loureiro LR, Feldmann A, et al. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells. Oncoimmunology. 2020; 9(1):1743036.

[13] Wang YF, Drum DL, Sun RC, et al. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nature Commun. 2023; 14(1): 5727.

[14] Wang T, Zhang KL, You FT, et al. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. Life Sciences. 2023; 331:122024.

[15] Zhou M, Chen M, Shi B, et al. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling. Mol Ther. 2022; 30(11): 3379-3393.

[16] Quach HT, Skovgard MS, Villena-Vargas J, et al. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy. Cancer Immunol Res. 2023; 11(10): 1314-1331.

[17] Puebla-Osorio N, Fowlkes NW, Barsoumian HB, et al. Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front Oncol. 2024; 14:1407143.

[18] Akhavan D, Subham S, Jeppson JD, et al. Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Cells. 2024; 13(13):1075.

[19] Patel RR, Barsoumian H, Verma V, Cortez MA, Welsh JW. Low-Dose Radiation Decreases Cancer-Associated Fibroblasts and May Increase T-Cell Trafficking into Tumors. Int J Radiat Oncol Biol Phys. 2020; 108(3): e530-e531.

[20] He K, Hong DS, Ke D, et al. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023; 33(4): 332-337.

[21] Potiron V, Clément-Colmou K, Jouglar E, et al. Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Lett. 2019; 457: 1-9.

[22] Sonveaux P, Brouet A, Havaux X, et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res. 2003; 63(5): 1012-9.

[23] Taylor E, Zhou J, Lindsay P, et al. Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy. Sci Rep. 2020; 10(1): 1638.

[24] McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome. 2018; 29(11-12): 843-865.

[25] Di Maggio FM, Minafra L, Forte GI, et al. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm (Lond). 2015; 12: 14. Published 2015 Feb 18.

[26] Rodriguez-Ruiz ME, Garasa S, Rodriguez I, et al. Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. Int J Radiat Oncol Biol Phys. 2017; 97(2): 389-400.

[27] Mondini M, Nizard M, Tran T, et al. Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Mol Cancer Ther. 2015; 14(6): 1336-45.

[28] Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013; 24(5): 589-602.

[29] Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5): 711-723.e4.

[30] Luo R, Firat E, Gaedicke S, Guffart E, Watanabe T, Niedermann G. Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. Clin Cancer Res. 2019; 25(23): 7243-7255.

[31] Wang C-L, Ho A-S, Chang C-C, et al. Radiotherapy enhances CXCR3highCD8+ T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells. Cancer Immunology, Immunotherapy. 2023; 72(6): 1865-1880.

[32] Stansborough RL, Al-Dasooqi N, Bateman EH, Keefe DM, Gibson RJ. Radiotherapy-induced gut toxicity: Involvement of matrix metalloproteinases and the intestinal microvasculature. Int J Radiat Biol. 2016; 92(5): 241-8.

[33] Zhang Y, He L, Sadagopan A, et al. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. Mol Cancer Ther. 2021; 20(3): 577-588.

[34] O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017; 9(399):eaaa0984.

[35] Kim SH, Go EM, Shin DH, Choi BK, Han C. Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice. Cells. 2022; 11(23):3894.

[36] Monjazeb AM, Giobbie-Hurder A, Lako A, et al. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021; 27(9): 2470-2480.

[37] Patel RR, Verma V, Barsoumian HB, et al. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021; 109(2): 352-364.

[38] Herrera FG, Ronet C, Ochoa de Olza M, et al. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022; 12(1): 108-133.

[39] Beauford SS, Kumari A, Garnett-Benson C. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. BMC Immunol. 2020; 21(1): 18.

[40] Muroyama Y, Nirschl TR, Kochel CM, et al. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2017; 5(11): 992-1004.

[41] Rutihinda C, Haroun R, Saidi NE, et al. Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy. Cancer Immunol Immunother. 2023; 72(5): 1089-1102.

[42] Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013; 73(9): 2782-2794.

[43] Laurent PA, Morel D, Meziani L, Depil S, Deutsch E. Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. Oncoimmunology. 2023; 12(1):2158013.

[44] Kang Y, Hirano K, Suzuki N, et al. Increased expression after X-irradiation of MUC1 in cultured human colon carcinoma HT-29 cells. Jpn J Cancer Res. 2000; 91(3): 324-330.

[45] Pocaterra A, Catucci M, Mondino A. Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy. Curr Opin Immunol. 2022; 74: 53-59.

[46] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9): 1050-1059.

[47] Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13(1): 54-61.

[48] Liao Y, Liu S, Fu S, Wu J. HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity. Onco Targets Ther. 2020; 13: 6859-6871. Published 2020 Jul 14.

[49] Chang Y, Chang M, Bao X, Dong C. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment. Bioact Mater. 2024; 42: 379-403.

[50] Lhuillier C, Rudqvist NP, Yamazaki T, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021; 131(5):e138740.

[51] Liu CX, Shao J, Dong YB, et al. Advanced HCC Patient Benefit From Neoantigen Reactive T Cells Based Immunotherapy: A Case Report. Front Immunol. 2021; 12685126.

[52] Arnold KM, Flynn NJ, Raben A, et al. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. Cancer Growth Metastasis. 2018; 11:1179064418761639.

[53] Herrera FG, Romero P, Coukos G. Lighting up the tumor fire with low-dose irradiation. Trends Immunol. Mar 2022; 43(3): 173-179.

[54] Farhood B, Khodamoradi E, Hoseini-Ghahfarokhi M, et al. TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury. Pharmacol Res. 2020; 155:104745.

[55] Barsoumian HB, Ramapriyan R, Younes AI, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020; 8(2):e000537.

[56] Ochoa-de-Olza M, Bourhis J, Coukos G, Herrera FG. Low-dose irradiation for reversing immunotherapy resistance: how to translate?. J Immunother Cancer. 2022; 10(7):e004939.

[57] Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15(7): 409-425.

[58] Chiang CS, Fu SY, Wang SC, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012; 2:89.

[59] Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol. 2016; 120(2): 185-194.

[60] Sonanini D, Griessinger CM, Schörg BF, et al. Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Theranostics. 2021; 11(16): 7700-7714.

[61] Rao P, Furst L, Meyran D, et al. Advances in CAR T cell immunotherapy for paediatric brain tumours. Front Oncol. 2022; 12:873722.

[62] Keisari Y, Kelson I. The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules. Cells. 2021; 10(2):228.

[63] Zhou Z, Guan B, Xia H, Zheng R, Xu B. Particle radiotherapy in the era of radioimmunotherapy. Cancer Lett. 2023; 567:216268.

[64] Nickoloff JA, Sharma N, Taylor L. Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy. Genes (Basel). 2020; 11(1):99.

[65] Huang Q, Hu J, Chen L, et al. Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis. Cancer Immunol Immunother. 2023; 72(12): 4077-4088.

[66] Ran J, Wang J, Dai Z, et al. Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions. Front Public Health. 2021; 9:666282.

[67] Ohkubo Y, Iwakawa M, Seino K, et al. Combining carbon ion radiotherapy and local injection of α-galactosylceramide-pulsed dendritic cells inhibits lung metastases in an in vivo murine model. Int J Radiat Oncol Biol Phys. 2010; 78(5): 1524-1531.

[68] Salomon N, Helm A, Selmi A, et al. Carbon Ion and Photon Radiation Therapy Show Enhanced Antitumoral Therapeutic Efficacy With Neoantigen RNA-LPX Vaccines in Preclinical Colon Carcinoma Models. Int J Radiat Oncol Biol Phys. 2024; 119(3): 936-945.

[69] Chiblak S, Tang Z, Lemke D, et al. Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight. 2019; 4(2): e123837.

[70] Zhou H, Yang P, Li H, et al. Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice. Cell Death Discov. 2021; 7(1): 332.

[71] Hu W, Pei Y, Ning R, et al. Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer. J Cancer Res Clin Oncol. 2023; 149(8): 4533-4545.

[72] Pignalosa D, Lee R, Hartel C, et al. Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions. Radiother Oncol. 2013; 109(2): 256-261.

[73] Liu S, He X, Liang S, Wu A, Liu L, Hu W. Carbon ion irradiation mobilizes antitumor immunity: from concept to the clinic. Radiat Oncol. 2025; 20(1): 85.

[74] Zhao C, Meng X, Li Y, et al. Circadian clock gene BMAL1 inhibits the proliferation and tumor-formation ability of nasopharyngeal carcinoma cells and increases the sensitivity of radiotherapy. Chronobiol Int. 2022; 39(10): 1340-1351.

[75] Lin X, Liu Z, Dong X, et al. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Transl Med. 2024; 22(1): 929.

[76] Zhang B, Hu M, Ma Q, et al. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy. Mol Ther. 2023; 31(7): 2105-2119.

[77] Sun T, Li Y, Yang Y, Liu B, Cao Y, Yang W. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma. Cell Death Dis. 2022; 13(10): 875.

[78] Chen C, Gu YM, Zhang F, et al. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology. 2021; 10(1):1901434.

[79] Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell. 2019; 36(5): 471-482.

[80] Liu M, Wang X, Li W, et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020; 9(8): 72.

[81] Liang LB, Huang XY, He H, Liu JY. Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database. Pharmgenomics Pers Med. 2020; 13: 365-373.

Rights & permissions

2026 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.